PP
CRL icon

Paloma Partners’s Charles River Laboratories CRL Stock Holding History

Paloma Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,600
Closed -$984K – 1065
2022
Q2 		$984K Buy
4,600
+1,757
+62% +$429K 0.03% 430
2022
Q1 		$807K Buy
2,843
+708
+33% +$218K 0.02% 521
2021
Q4 		$804K Buy
+2,135
New +$829K 0.01% 827
2021
Q2 		– Sell
-11,670
Closed -$3.38M – 1850
2021
Q1 		$3.38M Buy
11,670
+10,532
+925% +$2.93M 0.07% 241
2020
Q4 		$284K Sell
1,138
-3,342
-75% -$796K 0.01% 1198
2020
Q3 		$1.01M Buy
4,480
+115
+3% +$23.9K 0.03% 727
2020
Q2 		$761K Buy
4,365
+2,091
+92% +$334K 0.01% 1035
2020
Q1 		$287K Sell
2,274
-13,909
-86% -$2.09M 0.02% 709
2019
Q4 		$2.47M Buy
16,183
+14,326
+771% +$1.98M 0.04% 502
2019
Q3 		$246K Buy
+1,857
New +$249K 0.01% 1646
2019
Q2 		– Sell
-13,969
Closed -$2.03M – 1793
2019
Q1 		$2.03M Buy
13,969
+10,850
+348% +$1.43M 0.05% 441
2018
Q4 		$353K Sell
3,119
-4,386
-58% -$549K 0.01% 803
2018
Q3 		$1.01M Buy
+7,505
New +$926K 0.02% 735
2017
Q4 		– Sell
-4,100
Closed -$443K – 1941
2017
Q3 		$443K Sell
4,100
-13,437
-77% -$1.38M 0.01% 1590
2017
Q2 		$1.77M Sell
17,537
-8,932
-34% -$822K 0.02% 836
2017
Q1 		$2.38M Buy
26,469
+20,331
+331% +$1.73M 0.03% 677
2016
Q4 		$468K Buy
6,138
+1,600
+35% +$122K ﹤0.01% 1538
2016
Q3 		$378K Sell
4,538
-13,820
-75% -$1.16M ﹤0.01% 1528
2016
Q2 		$1.51M Buy
+18,358
New +$1.51M 0.02% 889
2016
Q1 		– Sell
-38,500
Closed -$3.1M – 1877
2015
Q4 		$3.1M Buy
38,500
+4,804
+14% +$346K 0.08% 219
2015
Q3 		$2.14M Buy
33,696
+21,978
+188% +$1.58M 0.05% 317
2015
Q2 		$824K Sell
11,718
-15,133
-56% -$1.12M 0.02% 854
2015
Q1 		$2.13M Buy
+26,851
New +$1.98M 0.06% 286
2014
Q1 		– Sell
-5,612
Closed -$298K – 736
2013
Q4 		$298K Buy
+5,612
New +$282K 0.01% 807

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Paloma Partners's CRL Position: Q3 2022 in Review

Paloma Partners sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 4,600 shares — an estimated $984K sold.

Paloma Partners first reported a position in CRL in Q4 2013 and held it in 24 quarters. The position peaked at $3.38M in Q1 2021. 582 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Paloma Partners reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
  • Paloma Partners sold 4,600 Charles River Laboratories shares in Q3 2022, an estimated $984K.
  • Paloma Partners first reported a position in Charles River Laboratories in Q4 2013 and held it in 24 quarters.
  • Paloma Partners's Charles River Laboratories position peaked at $3.38M in Q1 2021.
  • 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Paloma Partners's 13F filing for Q3 2022, filed 14 Nov 2022.